Scientists test 'Tiny Warhead' therapy to target deadly recurrent brain tumors
NCT ID NCT07422363
Summary
This early-stage study is testing a new two-drug combination for glioblastoma, an aggressive brain cancer that has returned after initial treatment. The first drug is a radioactive antibody designed to find and deliver radiation directly to cancer cells. The second drug is an immunotherapy intended to help the patient's own immune system fight the cancer. The main goals are to find the safest dose and see if the treatment shows any early signs of slowing the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA IDH WILDTYPE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.